Ann: Update on BLA for Graft Versus Host Disease, page-662

AFR's Jemima Whyte, Senior Reporter is a follower of HotCopper, here's some extracts from todays edition, long but good article by the way, worth a look:

"Mesoblast investors are used to trying to read the tea leaves ahead of a major announcement. August 2 – the deadline the US Food and Drug Administration had given to rule on its latest application – proved to be no different.

Ahead of the response about approving stem cell-based injectable treatment for acute graft versus host disease in children, investors were trawling LinkedIn for clues.

Word had whipped around that seven new job ads for Ryoncil Centre of Excellence managers across the US had been posted just before the Australian market opened and Mesoblast shares entered a trading halt.

Was it a signal that this company-making approval was – finally – in the bag?

This time, the tea leaves were read wrong, again.

Its retail supporters had remained optimistic in the lead-up to the FDA decision. Threads on HotCopper, an online stock chat platform, set up this week include “How will you celebrate when the FDA gives the Tick” and “2023: The Final Countdown”.

By Thursday afternoon, when no FDA update had been provided, the mood was becoming slightly less upbeat. “If the announcement does not have ‘Approved’ in the title, The End,” wrote one poster, though with far fewer comments and views than the others."